| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-09 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.37 | 3e-09 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.33 | 3e-08 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-08 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.3 | 4e-06 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.19 | 6e-06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 1e-05 |